PeproMene Bio gibt die Veröffentlichung bahnbrechender Ergebnisse einer klinischen Phase-1-Studie in The Lancet bekannt, die tiefe und anhaltende vollständige Remissionen bei rezidivierten/refraktären B-Zell-Lymphomen belegen, auch nach vorherigem Versagen einer CD19-CAR-T-Zell-Therapie

PeproMene Bio's Phase 1 PMB-CT01 BAFF-R CAR-T study, published in The Lancet, produced complete remissions in 7 of 9 patients (80%) with relapsed/refractory B-cell non-Hodgkin lymphoma, including 4 of 6 patients whose disease progressed after CD19 CAR-T therapy. All complete remissions remained ongoing at the data cutoff, with the longest lasting 35 months and no reported relapses; CRS and ICANS events were limited to grade 1. The trial has expanded to multiple U.S. centers, supported by up to $11 million from IFLI for development in relapsed/refractory follicular lymphoma.

Analysis

There is no direct public-equity vehicle: PeproMene is private, so the news is not independently monetizable through its shares. The read-through is modestly negative for CD19-centric CAR-T franchises—Gilead (Kite), Bristol Myers Squibb and Novartis—only if BAFF-R targeting reproduces efficacy in a materially larger, multicenter dataset. The strategically important mechanism is not near-term displacement but creation of a post-CD19 relapse treatment sequence, which could expand the treated population and preserve CAR-T referral volumes rather than cannibalize first-line CD19 products.

The commercial hurdle is substantial. A very small, single-center, selected population cannot establish durability, manufacturing reproducibility, or comparative safety; outpatient administration remains a hypothesis until confirmed across sites and in patients with heavier comorbidity. For incumbent CAR-T suppliers, a viable BAFF-R product could ultimately pressure salvage-line pricing and reduce the value of CD19 retreatment, but autologous manufacturing capacity, vein-to-vein time, reimbursement, and the need for prospective registrational endpoints make this a 3-5 year competitive issue, not an earnings catalyst.

The contrarian view is that the signal may be more valuable to CD19 CAR-T incumbents than harmful: a credible sequential option can make physicians more willing to deploy CD19 CAR-T earlier, knowing antigen-loss relapse is not necessarily terminal. The key falsifier is whether multicenter expansion demonstrates comparable complete-response durability at 12 months, manageable severe CRS/ICANS rates, and reliable manufacturing turnaround; failure on any of these would return BAFF-R to a niche academic-platform story.

Key Decisions for Investors

• No immediate directional trade in GILD, BMY or NVS: the clinical signal is too early and PeproMene is private; treat subsequent multicenter updates as a competitive-monitoring event rather than an earnings revision catalyst.
• Maintain a 6-18 month watchlist on GILD, BMY, NVS and AUTL for evidence that post-CD19 relapse sequencing expands total CAR-T utilization. Upgrade the read-through only after a larger cohort reports 12-month durability and operational metrics by site.
• For portfolios already long GILD or BMY, do not hedge solely on this publication. Reassess salvage-line CAR-T assumptions if BAFF-R data show reproducible efficacy in at least several dozen patients and a registrational path; that would increase long-term pricing and share risk for CD19-only platforms.
• Monitor private-market financing or a potential IPO/licensing transaction involving PeproMene as the more actionable event. A strategic partnership with a major cell-therapy manufacturer would validate manufacturing scalability and create a clearer public-equity beneficiary or loser.